Patents Represented by Attorney, Agent or Law Firm Rae-Venter Law Group P.C.
  • Patent number: 6825332
    Abstract: Genes for familial hemeplegic migraine (FHM), episodic ataxia type-2 (EA-2), common forms of migraine, and other episodic neurological disorders, such as epilepsy, have been mapped to chromosome 19p13. A brain-specific P/Q type calcium channel subunit gene, covering 300 kb with 47 exons is provided. The exons and their surroundings reveal polymorphic variations and deleterious mutations that are linked to various types of cation channel dysfunctions causing episodic neurological disorders in man or animals.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: November 30, 2004
    Assignee: Rijksuniversiteit Tel Leiden
    Inventors: Rune Robert Isak Erik Frants, Michel Dominique Ferrari, Gisela Marie Terwindt, Roel André Ophoff
  • Patent number: 6495155
    Abstract: An injectable slow-release partial opioid agonist or opioid antagonist formulation is provided comprising a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, a partial opioid agonist or opioid antagonist is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances. Of particular interest are the drugs buprenorphine, methadone and naltrexone.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: December 17, 2002
    Assignee: Southern Research Institute
    Inventors: Thomas R. Tice, Jay K. Staas, Teresa M. Ferrell, Peter Markland
  • Patent number: 6475508
    Abstract: Described are compositions, methods, and articles of manufacture for the closure of retinal breaks with a non-toxic polymer. Transformation to a gel-like coat is achieved by photochemical reactivity, chemical reactivity, and by physicochemical response.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: November 5, 2002
    Assignees: Regents of the University of California, California Institute of Technology
    Inventors: Daniel M. Schwartz, Jeffrey A. Hubbell, Alexander R. Irvine
  • Patent number: 6472415
    Abstract: Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. The compounds bind specifically to the androgen receptor and find use in indications associated with the androgen receptor, such as cell hyperplasia dependent on androgens, hirsutism, acne and androgenetic alopecia.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: October 29, 2002
    Assignee: Biophysica, Inc.
    Inventors: Milos Sovak, Allen L. Seligson, James Gordon Douglas, III, Brian Campion, Jason W. Brown
  • Patent number: 6465791
    Abstract: Diyne monomers are used as photochromic agents in devices or formulations. The devices and formulations may be applied to body parts for semi-pemanent attachment at various sites to allow for detection of levels of ultraviolet radiation. Clear films may be placed on eyeglass lenses to detect UV radiation occurring between the lens and the eye.
    Type: Grant
    Filed: March 30, 2000
    Date of Patent: October 15, 2002
    Assignee: Segan Industries
    Inventors: Hans O. Ribi, David A. Frankel
  • Patent number: 6358699
    Abstract: ADMA is determined in a physiological sample by first removing interfering components: proteins by precipitation; and amines and citrulline, by means of a cation exchange column, followed by enzymatic hydrolysis of the ADMA to citrulline with DDAH. The citrulline is then determined spectrophotometrically.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: March 19, 2002
    Assignees: Cooke Pharma, Panorama Research, Inc.
    Inventors: Robert F. Balint, Mitchell Wayne Mutz, John P. Cooke
  • Patent number: 6350576
    Abstract: Nucleic acid sequence probes are provided for the detection of lesions associated with neoplastic cells. The sequences can be used for identifying the locus associated with the lesion, for determining cancer susceptibility of cells, as well as categorizing and characterizing tumor cells for prognosis and therapy.
    Type: Grant
    Filed: December 21, 1995
    Date of Patent: February 26, 2002
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Michael Wigler, Nikolai Lisitsyn
  • Patent number: 6329570
    Abstract: Novel methods are provided whereby encoding sequences preferentially directing gene expression in ovary tissue, particularly in very early fruit development, are utilized to express genes encoding isopentenyl transferase in cotton ovule tissue. The methods permit the modification of the characteristics of boll set in cotton plants and provide a mechanism for altering fiber quality characteristics including fiber dimension and strength.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: December 11, 2001
    Assignee: Calgene, LLC
    Inventor: Belinda Martineau
  • Patent number: 6319693
    Abstract: Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (CAV)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies. The use of CAV-specific antibodies thus obtained.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 20, 2001
    Assignee: Leadd B.V.
    Inventors: Matheus H. M. Noteborn, Gerben F. de Boer
  • Patent number: 6306425
    Abstract: An injectable slow-release naltrexone formulation is provided comprising naltrexone in a poly(D,L-lactide) matrix with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, naltrexone is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: October 23, 2001
    Assignee: Southern Research Institute
    Inventors: Thomas R. Tice, Jay K. Staas, Teresa M. Ferrell
  • Patent number: 6300493
    Abstract: Methods and compositions are provided for the modification of polysaccharide structures using polysaccharidase binding or catalytic domains either alone or in tandem to modify the structure of polysaccharides. These methods and compositions are exemplified by the use of cellulase binding and catalytic domains to polish cotton, and to alter dying characteristics, texture and porosity of cellulose fibers.
    Type: Grant
    Filed: October 13, 1998
    Date of Patent: October 9, 2001
    Assignee: University of British Columbia
    Inventors: Neil R. Gilkes, Douglas G. Kilburn, Robert C. Miller, Jr., Anthony Warren
  • Patent number: 6288301
    Abstract: A method for treating diabetes mellitus by administering composition providing a gastrin/CCK receptor ligand, e.g. a gastrin, and an EGF receptor ligand, e.g. TGF&agr;, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g. a TGF&agr; gene.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: September 11, 2001
    Assignees: Waratah Pharmaceuticals, Inc., The General Hospital Corporation
    Inventors: Ronald V. Nardi, Stephen J. Brand
  • Patent number: 6277606
    Abstract: Methodology is provided for developing probes for identifying sequence differences between two related DNA populations, sets of DNA fragments or collections of restriction-endonuclease-cleaved DNA or cDNA. The method employs an initial stage to obtain a representation of both DNA populations, namely using the PCR to produce relatively short fragments, referred to as amplicons. Tester amplicons containing target DNA, sequences of interest, are ligated to adaptors and mixed with excess driver amplicons under melting and annealing conditions, followed by PCR amplification. The process may be repeated so as to greatly enrich the target DNA. Optionally, the target DNA may then be cloned and the DNA used as probes.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: August 21, 2001
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Michael Wigler, Nikolai Lisitsyn
  • Patent number: 6238669
    Abstract: Circular double-stranded replication intermediates were identified in low-molecular-weight DNA of cells of the avian leukemia virus-induced lymphoblastoid cell line 1104-X-5 infected with chicken anemia virus (CAV). To characterize the genome of CAV, we cloned linearized CAV DNA into the vector pIC20H. Transfection of the circularized cloned insert into chicken cell lines caused a cytopathogenic effect, which was arrested when a chicken serum with neutralizing antibodies directed against CAV was added. The 2,319-bp cloned CAV DNA contained all the genetic information needed for the complete replication cycle of CAV. The CAV genome probably contains only one promoter region and only one poly(A) addition signal. Southern blot analysis using oligomers derived from the CAV DNA sequence showed that infected cells contained double- and single-stranded CAV DNAs, whereas purified virus contained only the minus strand.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: May 29, 2001
    Assignee: Leadd, bv
    Inventors: Mathews H. M. Noteborn, Gerden F. De Boer
  • Patent number: 6222097
    Abstract: Novel DNA constructs are provided which may be used as molecular probes or inserted into a plant host to provide for modification of transcription of a DNA sequence of interest in ovary tissue, particularly in very early fruit development. The DNA constructs comprise a transcriptional initiation regulatory region associated with gene expression in ovary tissue from immediately prior to anthesis through flower senescence.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: April 24, 2001
    Assignee: Calgene, LLC
    Inventors: Kevin E. McBride, David M. Stalker
  • Patent number: 6184249
    Abstract: Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. The compounds bind specifically to the androgen receptor and find use in the therapy of indications associated with the androgen receptor, such as, hirsutism, acne and androgenetic alopecia, and in the therapy and diagnosis of cell hyperplasia dependent on androgens.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: February 6, 2001
    Assignee: Biophysica, Inc.
    Inventors: Milos Sovak, Allen L. Seligson, James Gordon Douglass, III, Brian Campion, Jason W. Brown
  • Patent number: 6176962
    Abstract: Methods are provided for the fabrication of polymeric microchannel structures having enclosed microchannels of capillary dimension. The microchannel structures are constructed of a base plate and a cover, sealed together. Microchannel structures having walls of a plastic material are formed in a generally planar surface of at least the base plate. The cover has at least one generally planar surface, and the microchannel structures are enclosed by bonding the planar surfaces of the cover and the base plate together. In some embodiments the surfaces of the cover and base plate are both of plastic material, and are directly thermally bonded. In some embodiments a bonding material is applied to one of the surface prior to bringing the surfaces together. Suitable bonding materials are disclosed.
    Type: Grant
    Filed: June 18, 1997
    Date of Patent: January 23, 2001
    Assignee: Aclara Biosciences, Inc.
    Inventors: David S. Soane, Zoya M. Soane, Herbert H. Hooper, M. Goretty Alonso Amigo
  • Patent number: 6174700
    Abstract: A compound having a polysaccharide binding domain such as contained by a cellulose and essentially lacking in polysaccharidase activity is purified from other ingredients in a mixture using an affinity partition system. A mixture containing the compound is contacted with a system containing as a first phase an aqueous solution of oligosaccharide polymer such as cellulose and as a second phase a solution of a polymer such as a poly(ethylene glycol)-poly(propylene glycol) copolymer. The compound petitions into the first phase and binds to the oligosaccharide polymer, preferably with a Ka of 103 to 107, to form a complex. The complex is collected, and the compound is dissociated from the oligosaccharide polymer. The compound may be formed of a non-peptide chemical moiety or a peptide moiety linked to a polypeptide having the polysaccharide binding domain.
    Type: Grant
    Filed: July 24, 1995
    Date of Patent: January 16, 2001
    Assignee: University of British Columbia
    Inventors: Charles A. Haynes, Peter Tomme, Douglas G. Kilburn
  • Patent number: 6162461
    Abstract: The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. The immunogenic properties of the chicken anemia virus (CAV) proteins produced separately or together in insect-cell cultures were analyzed by inoculating them into chickens. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 19, 2000
    Assignee: Leadd B.V.
    Inventors: Matheus Hubertus Maria Noteborn, Guus Koch
  • Patent number: RE37727
    Abstract: Methods and compositions are offered for reducing nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia), where intradermal delivery of lidocaine is maintained for a predetermined period of time. The lidocaine appears to specifically affect the damaged nerve fibers, while leaving the undamaged and normal nerve fibers with retention of response to other stimuli. Lidocaine formulations are provided which allow for the necessary dosage of the lidocaine in the dermis during the period of treatment. The formulation may be covered with an occlusive or non-occlusive dressing, which protects the lidocaine formulation from mechanical removal and enhances the transport of the lidocaine into the dermis. Long term relief is realized after maintenance of the administration of lidocaine has been terminated.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: June 4, 2002
    Assignee: Hind Health Care
    Inventor: Harry W. Hind